Lapsuuden aivokasvaimen lääkekehityksessä on suuri läpimurto. Lasten aivokasvaimet ovat yleisempi pahanlaatuinen sairaus lapsilla. Viimeaikaiset tutkimukset ovat osoittaneet, että uusi cocktaillääke voi hoitaa yleisiä lapsuuden aivokasvaimia.
Cancer Cell” magazine recently announced that in the UK, about 400 children develop brain kasvaimet each year, of which the prevalence of boys is slightly higher than that of girls.
Are we able to take advantage of the results of tumor gene testing and tailor-made treatments, a strategy often referred to as personalized medicine? This treatment strategy can produce very good results for patients with brain tumors.
Neural myeloblastoma (medulloblastoma) is one of the most common pahanlaatuiset kasvaimet of the cerebellum. This aivokasvain grows rapidly and most often occurs in children around the age of 5. Hoitovaihtoehdot include surgery, radiation, and chemotherapy. Although great progress has been made in treatment methods and techniques, the success rate of treating myeloblastoma still lags far behind other children’s malignancies. In particular, myeloblastoma is a highly aggressive malignancy. Only 40% of patients with medulloblastooma survive, compared with other tumors of a less severe type-with a survival rate of more than 80%.
Researchers in the United States have discovered a new combination therapy for the treatment of highly aggressive neuroblastooma. In laboratory tests, the drug killed syöpä cells without any toxicity to normal cells, and researchers hope to conduct clinical trials of the drug. Robert Wechsler-Reya, an adjunct professor at the Sanford Burnham Prebys Medical Institute, said: “Our goal is to confirm that the drug has low toxicity properties. Because doctors and patients in this case urgently require new clinical treatment options, we will soon apply the drug from the laboratory to clinical treatment.
Yhdistämällä muiden lääkkeiden kanssa uusia kasvaimia estäviä yhdisteitä seulotaan in vitro ja in vivo.
Kliiniset tutkimukset for neuroblastoma are often very challenging because of the limited number of patients. In addition, coupled with the variability of the disease, most treatments are only effective for one subtype of patient. Understanding which patients will respond to this treatment is one of the main goals of the trial.
"Jos voimme kehittää räätälöityjä hoitoja, jotka perustuvat kasvaingeeneihin - strategiaan, jota yleensä kutsutaan yksilölliseksi hoidoksi, tämä voi tuoda valtavan evankeliumin potilaille, joilla on tiettyjä kasvaimia."
Neuroblastoomaa on neljä erilaista tyyppiä, ja potilailla, joilla on kolmas kasvainryhmä, on huonoin ennuste - vain 40% potilaista selviää pitkäaikaisesti. Sitä vastoin muiden neuroblastoomien pitkäaikainen eloonjääminen on suhteellisen optimistista, ja noin 80% potilaista voi selviytyä pitkällä aikavälillä.
Suurimmalla osalla kolmannesta neuroblastoomapotilaiden ryhmästä on korkea MYC-onkogeenin ilmentyminen, mikä on syynä hallitsemattomaan solujen jakautumiseen ja kasvainten muodostumiseen.
There was a study on mice with a third type of neural tube solukasvaimet that showed histone deacetylase inhibitors (HDACIs) and phosphatidylinositol 3-kinase inhibitors (PI3KIs) might stop mice and people from making neurotubular glioblastomas without doing too much damage to normal cells.
We found several histone deacetylase inhibitors that can kill MYC oncogene-activated neural tube cell tumors without harming normal cell agents (HDACIs),” said Pei Yanxin, an assistant professor at the National Children’s Medical Center Washington DC: ssä
The most effective of these compounds is panobinostat, which has entered clinical trials in other syöpätyypit, but has not yet been tested on neuroblastoma.” Dr. Kun-Wei, a postdoctoral researcher at Stanford University, added: “Several other studies have revealed that the mechanism of action of panobinostat is to promote the activation of the FOXO1 gene that can interfere with the oncogenes of MYC.
Phosphatidylinositol 3-kinase inhibitors (PI3KIs) are also thought to have the effect of activating the FOXO1 gene. We hypothesized that panobinostat and phosphatidylinositol 3-kinase inhibitors (PI3KIs) could work together to block Syöpäsolu eloonjääminen.
“It is true that the combined treatment of these two drugs can significantly increase the survival of patients with tumors carrying the MYC gene compared to using a single drug alone.”
